AnaCardio exercises option to license a program in heart failure from Helsinn
Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has exercised its option to license from Helsinn a program in heart failure, a condition which is associated with poor quality of life, poor prognosis and which remains a major unmet medical need. Under the